Get the latest tech news
Alzheimer’s prevention hope as drug cuts deadly disease onset in half | A long-term trial has found that a discontinued drug halved the onset of a genetic form Alzheimer's, from all but 100% to 50%.
A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in people with a genetic predisposition to the devastating condition. Right now, symptoms are almost 100% likely to develop in patients between the ages of 30 and 65.
As such, everyone was able to extend the trial – and this time all participants received ganternerumab, with a related external study (which ultimately saw the drug discontinued before the research reached its anticipated three-year period) serving as the control group. Ultimately, the cohort who had taken the drug in both the initial trial and the extension showed the strongest results, suggesting that long-term treatment well before symptoms are most likely to develop could be key to ganternerumab's success. “The Alzheimer’s Association looks forward with great anticipation to replication, extension and expansion of this genuinely unprecedented and groundbreaking research, and we have made a significant investment in ensuring these important scientific questions can be investigated.
Or read this on r/tech
